| Applied Genetic Technologies is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for people suffering from rare and debilitating diseases. Co.'s initial focus is in the field of ophthalmology, where it has wholly owned clinical-stage programs in X-linked retinitis pigmentosa and achromatopsia, and an optogenetics program. Co.'s preclinical pipeline includes a program in dry age-related macular degeneration, two programs targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis, and a program in otology through its collaboration with Otonomy, Inc. We show 39 historical shares outstanding datapoints in our AGTC shares outstanding history coverage, used to compute AGTC market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AGTC market cap history over the course of time is important for investors
interested in comparing AGTC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AGTC versus a peer is one thing; comparing
AGTC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AGTC can fluctuate over the course of history.
With this page we aim to empower investors researching AGTC by allowing them to research the AGTC market cap history.